ProfileGDS5678 / 1459195_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 40% 40% 40% 39% 41% 41% 48% 40% 40% 40% 39% 40% 40% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9420539
GSM967853U87-EV human glioblastoma xenograft - Control 22.9101940
GSM967854U87-EV human glioblastoma xenograft - Control 32.9154840
GSM967855U87-EV human glioblastoma xenograft - Control 42.8627940
GSM967856U87-EV human glioblastoma xenograft - Control 52.8401939
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0293741
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9976241
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1451248
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8990740
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8923640
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9005440
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8645239
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9104940
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9032840